Latest posts tagged with #Phase3 on Bluesky
🚨 Latest #Phase3 Update!
🔷 In the Phase III LEAP-010 trial, lenvatinib + pembrolizumab improved PFS (6.2 vs 2.8 months; HR 0.64) and ORR (46.1% vs 25.4%) versus pembrolizumab alone in first-line PD-L1 CPS ≥1 R/M HNSCC.
🚨 Latest #Phase3 Update!
🔷 In a Phase III randomized trial (RECITE), Romiplostim significantly reduced chemotherapy dose modifications due to chemotherapy-induced thrombocytopenia (CIT) in patients receiving oxaliplatin-based chemotherapy for gastrointestinal cancers.
🚨 Latest #Phase3 Trial Update!
🔷 The Phase III CAMPASS trial evaluates benmelstobart plus anlotinib versus pembrolizumab as first-line therapy in patients with PD-L1–positive advanced NSCLC.
🧬 Deramiocel is back under #FDA review for #DMD cardiomyopathy.
The agency lifted a prior CRL and set a new PDUFA date of August 22, 2026, continuing evaluation of Capricor’s cell therapy following new #Phase3 HOPE-3 data.
Visit the NeurologyLive website to read more‼️
#Neurology #MDAconference
🚨 Latest #Phase3 Trial Update!
🔷 Bristol Myers Squibb’s Phase 3 SUCCESSOR-2 trial reports positive outcomes with oral Mezigdomide in relapsed or refractory multiple myeloma.
🚨 Latest #Phase3 Update!
🔷 A biomarker analysis from the Phase III CONTINUUM and DIPPER trials developed a machine-learning classifier identifying three metabolic subtypes (MS1–MS3) in locoregionally advanced nasopharyngeal carcinoma (NPC) to better predict response to immunotherapy.
#Roche's oral BTK inhibitor #fenebrutinib has hit the spot in the final trial in its #phase3 programme, in relapsing #multiplesclerosis (RMS), and is now being prepared for #regulatory filings.
pharmaphorum.com/news/after-p...
🚨 Latest #Phase3 Trial Update!
🔷 Adjuvant treatment with KEYTRUDA® (pembrolizumab) plus WELIREG® (belzutifan) reduced the risk of disease recurrence or death by 28% compared to KEYTRUDA® alone in certain patients with earlier-stage Renal cell carcinoma (RCC).
🚨 Latest #Phase3 Trial Update!
🔷 SystImmune and Bristol Myers Squibb highlight Phase III interim topline results show promising efficacy for izalontamab brengitecan (Iza-bren) in previously treated unresectable or metastatic triple-negative breast cancer.
🚨 Latest #Phase3 Trial Update!
🔷 Bayer’s PEACE-3 trial demonstrates a significant overall survival (OS) benefit with radium-223 dichloride plus enzalutamide in patients with metastatic castration-resistant prostate cancer and bone metastases.
Phase 3️⃣ NEAT: EryDex missed its primary endpoint in ataxia-telangiectasia.
🧠 RmICARS change did not reach significance (P=.0851), and no CGI-S benefit was seen—though tolerability appeared favorable. Visit our website for more!
#ClinicalTrials #RareDisease #Neurology #Phase3
Starting at about 2:30pm (pacific), I'll be playing #Satisfactory having just started #Phase3!
▶ YouTube: youtube.com/@artgh0sts
▶ Twitch: twitch.tv/artgh0sts
Bayer to present new Phase III data for the investigational low-dose MRI contrast agent gadoquatrane at ECR 2026, featuring a 60% reduction in gadolinium dose.
stellanews.life/technology/8...
#MRI #Radiology #Bayer #ECR2026 #Gadoquatrane #Phase3 #MedicalImaging #ContrastAgent
#Lundbeck #phase3 #migraineprevention #migrainepreventiondrug #bocunebart #antiPACAPantibody #phase2b #PROCEEDtrial #intravenousbocunebart #LuAG09222 #monthlymigrainedays #MMD #PACAP #neuropeptide #pathophysiologyofmigraine #migrainetreatment #PACAPpathway #migrainepreventionmarket
zurl.co/M7FHE
Astellas reports positive Phase 3 STARLIGHT 2 results in Japan for fezolinetant in vasomotor symptoms
stellanews.life/technology/8...
#Menopause #VMS #Fezolinetant #Phase3 #Astellas
UCB showcases three-year hidradenitis suppurativa data at EHSF; BIMZELX (bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements
stellanews.life/technology/8...
#HidradenitisSuppurativa #HS #Bimekizumab #BIMZELX #EHSF #Phase3
リジェネロン、AAAAI 2026で免疫領域36演題発表へ
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI 2026
stellanews.life/technology/8...
AI impact rating（reference only）: ★★★★☆
This is an experimental indicator and not a guarantee of accuracy.
#AAAAI #Allergy #Dupilumab #Phase3 #Regeneron
Wondering where we’ve been? It may seem like we are hiding, but we’re still here in the vocal isolation booth 🎙️ getting ready for phase 3 of The Flip Phones. Watch this space for exciting news coming soon! 🔥 🎸 🎹 #theflipphones #newyear #phase3 #anticipation
Altimmune raises $75 million to advance pemvidutide, a promising therapy tackling serious liver and metabolic diseases.
longevity.technology/news/altimmu...
#longevity #liverhealth #biotechfunding #phase3 #metabolichealth #clinicaltrials
Bizarrap en el #Ultra de Miami, ¿pero qué mierda es esta? 🤮 #UMF #Ultra26 #UltraMiami #UMF2026 #BZRP #Bizarrap #Ultra2026 #UltraMiami2026 #Miami #Phase3 #BayFrontPark
Big news in neurology❗
Annexon has submitted an EMA marketing application for tanruprubart, a first-in-class C1q antibody for Guillain-Barré syndrome.
#Phase3 data show faster, more complete recovery & QoL gains. Read more below 👇
www.neurologylive.com/view/annexon...
#GBS #Neurology #Biotech
🔗 Read more: bit.ly/ONCOnews18D-01
#ONCOnews #OncoAlert #OncEd #OncologyNews #ImmunoOncology #ClinicalTrials #Phase3 #BladderCancer
🔗 Read more: bit.ly/ONCOnews16D-03
#ONCOnews #OncoAlert #OncEd #OncologyNews #DrugDevelopment #Phase3 #RareCancer
📊 Results also showed fewer rehospitalizations, reduced non-relapse mortality, and improvements in OS and GRFS; Orca-T is under FDA Priority Review with a target action date of April 6, 2026.
🔗 Read more: bit.ly/ONCOnews16D-02
#ONCOnews #OncoAlert #OncEd #OncologyNews #Immunotherapy #Phase3
🚨 Major #DMD breakthrough: Deramiocel hits its #Phase3 endpoint!
💪 54% slower loss of upper-limb function
❤️ 91% slower decline in cardiac function
A huge moment for Duchenne research and regulatory momentum. Read here: www.neurologylive.com/view/cell-th...
#RareDisease #Biotech #Neurology
Pharvaris announces positive Phase 3 results for oral deucrictibant in HAE. The drug showed rapid symptom relief in 1.28 hrs & was well-tolerated. Regulatory filings are planned for H1 2026.
#News #Pharvaris #deucrictibant #HAE #RareDisease #Phase3 #Biotech
Pharvaris announces positive Phase 3 results for oral deucrictibant in HAE. The drug showed rapid symptom relief in 1.28 hrs & was well-tolerated. Regulatory filings are planned for H1 2026.
#News #Pharvaris #deucrictibant #HAE #RareDisease #Phase3 #Biotech
🆕 #Phase3 data from the #EVOKE trials show semaglutide did not slow progression of early #AD
🔹 No significant benefit on CDR-SB, ADCS-ADL-MCI, or cognitive composites
🔹 #Biomarkers: reductions in pTau181/217 and hs-CRP, but no clinical impact
🔹 Read more: www.neurologylive.com/view/ctad-pr...
